Advanced Drug Delivery Systems for Colonic Disorders

Advanced Drug Delivery Systems for Colonic Disorders presents state-of-the-art methods for targeted drug delivery to the colon. These methods can prolong drug half-lives, improve bioavailability, optimize pharmacokinetics, and reduce medication dosing frequency. Chapters allow readers to not only become familiar with advancements, but also understand concepts by providing illustrations, figures, and informative tables. Contents cover an overview of colonic diseases, the cellular and molecular mechanisms involved, current and traditional therapeutic approaches, biomaterials, oral drug delivery methods, targeted drug delivery, nutraceuticals and herbal medicine approaches, prebiotics, probiotics and symbiotics, nanomedicine approaches, and the status of clinical trials. This book is the perfect resources for researchers in pharma, biomaterials, and nutrition to help familiarize them with new and upcoming therapeutic methods. Research physicians in GI can also benefit from reading this book for its clinical applications.

Sommario

1. Introduction to colonic disorders
Manvi Singh, Puru Goel, Mayank Phagna, Reena Badhwar, Zeenat Iqbal and Mohd. Aamir Mirza

2. Cellular and molecular mechanisms involved in colonic disorders
Simranjit Kaur, Arshdeep Singh, Harpreet Kaur, Jagbir Singh and Rajbir Bhatti

3. Current approaches for treatment of colonic disorder
Manish Gupta, Priya Sen, Mahendra Saini, Mahaveer Singh, Pawan Bagiyal, Pramod Kumar and
Gaurav Gupta

4. Polysaccharides based drug delivery systems for the treatment of colon diseases
Sadaf Arfi, Nimisha Srivastava and Deepti Dwivedi

5. Synthetic polymers as biomaterials for the treatment of colon diseases
Sundeep Chaurasia and Brahmeshwar Mishra

6. Mucoadhesive polymers as biomaterials for the treatment of colon disorders
Nitesh Kumar, Priyanka Verma, Varun Kumar, Rachel Kaul and Surbhi Mishra

7. Colon-responsive oral drug delivery for combating colonic disorders
Anindita Behera

8. Colon-responsive targeted drug delivery for treating colonic disorder
Anil K. Philip, Bassim I. Mohammad and Hayder A. Al-Aubaidy

9. Advancement in targeted drug delivery systems in managing colonic disorders
C. Sarath Chandran, Krishnameera Sajayan, Jeeva C. Soman, P.K. Anjana, K.K. Swathy, A.S. Vishnu and Shijina Kappally

10. Nutraceuticals and phytoceuticals in the treatment of colonic disorders
Nitin Verma, Jatin Kumar, Neha Kanojia, Komal Thapa and Kamal Dua

11. Role of Prebiotics, Probiotics and synbiotics in the management of colonic disorders
Faizan Naeem Razali, Wuen Yew Teoh, Muhammad Zaki Ramli, Ching-Yee Loo and Charles Gnanaraj

12. Era of biotics in managing colonic disorders
Shvetank Bhatt, K. Anitha, Sujit Kumar Sah, Nishant Prasad Apte, Sakina. Mullamitha and
Jamila Chechatwala

13. Innovations in liposomal drug delivery: paving the way for personalized cancer therapy
Alaa A.A. Aljabali, Mohammad A. Obeid, Mohamed El-Tanani and Murtaza M. Tambuwala

14. Nanoparticulate drug delivery systems for colonic disorders
Girish Kumar, Tarun Virmani, Ashwani Sharma, Reshu Virmani and Kamla Pathak
15. 3D printing-assisted colon-targeted drug delivery systems
Chandrakantsing Pardeshi, Ganesh Shevalkar, Mahesh Umbarkar, Dipak Bari, Kamalesh Mali,
Sameer Lakade and Monica Garc¿a

16. Radiopharmaceutical-based approaches for the determination of colon-targeting
efficiency
Akshita Arora, Anshul Sharma, Richa Kumari and Nitin Sharma

17. Colonic disorder management: challenges an prospects
Alan Raj, M. Sonal Sekhar and Angel Treasa Alex

18. Clinical trials and regulatory aspects of drug delivery system for colonic disorders
Riya Shivgotra, Manjot Kaur, Shubham Thakur, Bindu Soni, Hossamaldeen Bakrey and Subheet Kumar Jain

Info autore

Dr. Harish Dureja is Professor and Head, Department of Pharmaceutical Sciences, Maharshi Dayanand University, Rohtak. Dr. Dureja is also the Director, Centre for IPR Studies and Director, Professional Consultancy Cell. Dr. Dureja has more than 22 years of teaching experience. He also holds 18 years research experience in the field of nanoparticulate drug delivery, regulatory affairs and in silico ADME modeling. Dr. Dureja has been awarded with Gold-Medal for the best Ph.D. thesis and research projects worth 1.2 Crore from various funding agencies. He has filed an Indian patent and written a book and authored more than twenty five book chapters. He has published 265 publications in various international and national journals of repute. He worked as Chairman-Scientific Services Committee (LOC) during 69th IPC at Chitkara University, Raj-pura. He also worked as content writer for e-Pathashala program of Ministry of Human Resources Development for Post Graduate course of Pharmaceutical Sciences for the paper novel drug delivery system. He has delivered more than 180 invited Lectures in various conferences, seminars and symposiums and has guided 60 PG scholars and 10 students for doctoral work. He has been awarded the Gold-Medal for Best Ph.D. Thesis, Best Paper Award - Prof. M.L. Khorana Memorial Prize Award – 2005 and Dr. R.L. Nicore award - 2018. He has published six special issues as a Guest Editor for the Journals published by Bentham Science Publishers, and one issue published by Frontiers, Switzerland. He is currently also serving as President, Association of Pharmaceutical Teachers of India (APTI), Haryana State Branch.Prof Raimar Löbenberg holds a BS in Pharmacy from the Johannes Gutenberg-University, Germany. He received his PhD in Pharmaceutics from the Johann Wolfgang Goethe-University in Frankfurt in 1996 for his work on drug delivery using nanoparticles. He joined the University of Alberta in 2000, where he is now a Professor in Pharmaceutical Sciences. His research interests are inhalable nanoparticles to treat lung diseases such as lung cancer and tuberculosis. His lab regularly develops and characterises nanoparticles for various inflammatory diseases and cancer. His lab also hosts a unique pencentury device which assists in effectively delivering nanoparticles to the lungs of rodents. He holds a US patent for the delivery of nanoparticles to the lungs. Another major interest area is Biopharmaceutics, and predicting the oral performance of drugs and botanicals.
Prof Löbenberg is a founder and Director of the Drug Development and Innovation Centre at the University of Alberta. The Centre specialises in clinical trial material production, and holds a Health Canada site licence and a drug establishment licence. The Centre has controlled substance licences to synthesise psychedelics in a dedicated chemistry lab. The quality control lab has state-of-the-art analytical instruments and other pharmaceutically relevant performance test instruments. Prof Löbenberg is a former president of the Canadian Society for Pharmaceutical Sciences (2014-2015). He is a member and Vice Chair of the United States Pharmacopeia Dietary Supplement Expert Committee, a Vice Chair of the Specialty Committee of Traditional Chinese Medicine in Pharmaceutics of the World Foundation of Chinese Medicine Science, and a member of the Health Canada Scientific Advisory Committee on Pharmaceutical Sciences and Clinical Pharmacology, and of the Health Canada Scientific Advisory Committee on Opiate Abuse.
Dr. Sachin Kumar Singh, is working as professor and head of Pharmaceutical Chemistry and Pharmaceutical Analysis at School of Pharmaceutical Sciences, Lovely Professional University, India and visiting professor Australian Research Centre in Complementary and Integrative Medicine (ARCCIM), School of Public Health, Faculty of Health, University of Technology Sydney, Australia. He has many years of teaching and research experience. Dr. Singh has published more than 350 research papers with cumulative impact of 1300, authored several books, and dozens of book chapters. He is also featured under top 2% scientists of world as per the list of 2021, published by Stanford University, USA.
Muralikrishnan Dhanasekaran, is a Professor of Pharmacology and Toxicology at the Department of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University. He earned his Ph.D. in 1999 from the Jadavpur University, India, in neuropharmacology. From 1999-2001, he became a post-doctoral fellow at the University of Nebraska Medical Center, Omaha, Nebraska, and the Uni-versity of North Dakota School of Medicine and Health Sciences, Grand Forks, ND. He served as a re-search instructor of pharmacology at Texas A & M Health Sciences, Temple, TX. His major area of teaching and research is related to pathophysiology, pharmacology, and toxicology in dementia, movement disorders, addiction (substances of abuse-designer drugs, nicotine, alcohol), hyperglycemia, epilepsy, and aging. His research was funded by the Alzheimer’s Association and Pharmaceutical com-panies in the USA. He has over one hundred and thirteen peer-reviewed publications, fifty book chap-ters, and around four hundred abstracts in national and international meetings in the area of pharma-cology, toxicology, and natural bioactives. He has received several awards for teaching, service, and outreach. He has been an editor or on the editorial board for several books and journals including nat-ural products, pharmacology, toxicology, and neuropharmacology.Dr Kamal Dua is an Associate Professor in the Discipline of Pharmacy at UTS. Dr Dua has been recognised and named as one of Australia’s Top 250 researchers in 2025 and 2024 in Research Magazine by the Australian in the research discipline of Health and Medical sciences, and #1/research leader in the area of Pharmacology and Pharmacy (2025) and Toxicology (2024) respectively. With over 17 years of research experience, he has specialised in drug delivery targeting inflammatory diseases. Additionally, Dr Dua also leads drug delivery research at the Woolcock Institute of Medical Research. In this role, he focuses on advancing targets identified in research projects to develop innovative formulations, taking the first steps toward clinical translation. Dr. Dua’s research encompasses two complementary areas: drug delivery and immunology. His work explores how these disciplines can mutually benefit, contributing to the goal of promoting longer and healthier lives for the community. His commitment to synergy is reflected in his extensive publication record in reputable journals. Dr Dua’s research interests are centered on harnessing the pharmaceutical potential of modulating critical regulators, such as interleukins and microRNAs. He also specialises in developing new and effective drug delivery formulations for managing inflammation in chronic airway diseases and cancer.

Dettagli sul prodotto

• Con la collaborazione di: Muralikrishnan Dhanasekaran (Editore), Kamal Dua (Editore), Harish Dureja (Editore), Raimar Loebenberg (Editore), Sachin Kumar Singh (Editore), Sachin Kumar Singh (Editore)
• Editore: Elsevier
• Lingue: Inglese
• Formato: Tascabile
• Pubblicazione: 07.11.2023
• EAN: 9780443140440
• ISBN: 978-0-443-14044-0
• Peso: 450 g
• Categorie: Scienze sociali, diritto, economia > Economia > Singoli rami economici, branche; MEDICAL / Gastroenterology, MEDICAL / Pharmacology, Gastroenterology, Pharmacology, Manufacturing industries, Pharmaceutical industries